MedTrace Logo

Evaluation of ColdZyme® on Experimentally Induced Common Cold.

NCT02479750 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2019-02-07

No results posted yet for this study

Summary

This study evaluates the performance of ColdZyme® mouth spray on prevention of common cold symptoms on experimentally induced rhinovirus upper respiratory tract infection in healthy volunteers. Half of participants will receive ColdZyme® mouth spray while the other half will receive placebo.

Conditions

  • Common Cold

Interventions

DEVICE

ColdZyme® mouth spray

DEVICE

Placebo

Sponsors & Collaborators

  • Enzymatica AB

    lead INDUSTRY

Principal Investigators

  • Patrick Mallia, MD · NHLI, Imperial College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-23
Primary Completion
2016-07-25
Completion
2016-07-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02479750 on ClinicalTrials.gov